NCT00765427

Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers

A Phase 1a, Repeat-Dose Escalation Study to Investigate the Safety and Tolerability of a 7-Day Repeated Dose of Retinoid QLT091001 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: QLT Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Healthy volunteer subjects will receive retinoid QLT091001 once-daily for 7 days for safety observation.

Conditions

• Healthy Human Volunteers

Interventions

Type	Name	Description
DRUG	QLT091001	7-day repeated dose

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-10-03
• Last updated: 2009-03-30

Locations

1 site across 1 country: Canada